Rutherford Health - Directorate Change
RNS Number : 2621T
Rutherford Health PLC
23 November 2021
 

Rutherford Health Plc

Resignation of Non-Executive Director

Rutherford Health plc (AQSE: RUTH, "Rutherford" or "the Company"), a healthcare group committed to providing innovative cancer care of the highest quality, announces the resignation of Alain Baron as a Non-Executive Director of the Company with immediate effect.

Mike Moran, CEO said: "on behalf of the Rutherford board, I would like to thank Alain Baron for his contribution to Rutherford Health  plc since he joined the board in 2017 and wish him well in his future endeavours".

 

 

For more information, please contact:

 

Rutherford Health plc

Tel: +44 (0) 16 3381 0661

Michael Moran, Chief Executive Officer
Marcus King, Finance Director

Investors@therutherford.com

 

 

Grant Thornton (Corporate Adviser)

Tel: +44 (0) 20 7383 5100

Colin Aaronson / George Grainger

 

 

 

Instinctif Partners

Tel: +44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris /
Phil Marriage

Rutherford@Instinctif.com

 

 

Media House International

Tel: 07788 414 856 or 0207 710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

 

 

 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in WalesReadingNorthumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website:  www.rutherfordhealth.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGIBDBSSDDGBX ]]>